No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 41 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR New analysis estimates over 21 million UK adults will be obese... May 18, 2022 Charity ‘looks to the future with renewed optimism’ July 21, 2021 We’re asking scientists to tackle 9 of the toughest challenges in... October 14, 2020 Autumn and Letting Go September 29, 2021 Load more HOT NEWS Studies Delve Deep into the Protein Machinery of Cancer Cells Coping with Grief: An Interview with Author Rebecca Munn ¿Qué son los biosimilares para el tratamiento del cáncer? Study Aims to Reduce Lung Cancer Stigma by Teaching Health Professionals...
